Acute myelocytic leukemia after the use of cyclophosphamide in the treatment of polyarteritis nodosa.
The use of cyclophosphamide has been associated with the delayed appearance of neoplasms. We report a woman who developed myelodysplastic syndrome leading to acute myelocytic leukemia, 4 years after receiving 13 g of cyclophosphamide over 6 months for severe polyarteritis nodosa. Cytogenetic abnormalities typical of damage induced by alkylating agents, including partial deletions of chromosomes 5 and 7, were present. This case represents the first reported occurrence of cyclophosphamide associated malignancy in polyarteritis nodosa.
Escalante
A
A
Arthritis Service, Rancho Los Amigos Medical Center, Downey, CA 90242.
Kaufman
R L
RL
Beardmore
T D
TD
D000328:Adult; D002872:Chromosome Deletion; D002889:Chromosomes, Human, Pair 2; D002895:Chromosomes, Human, Pair 5; D002897:Chromosomes, Human, Pair 7; D003520:Cyclophosphamide / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007621:Karyotyping; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced* / Q000235:genetics; D010488:Polyarteritis Nodosa / Q000188:drug therapy*
D003520:Cyclophosphamide